It has been reported that there is a high prevalence (39–57.8%) of PLMS in PD patients and that reduced striatal dopamine transporter binding and nigrostriatal dopaminergic cell loss might be the underlying reason for the comorbidity of PD and PLMS (44–46). This evidence concerns the gene SLC6A3 and Parkinson disease.